Literature DB >> 24259495

Soluble form of FGFR2 with S252W partially prevents craniosynostosis of the apert mouse model.

Jumpei Morita1, Masataka Nakamura, Yukiho Kobayashi, Chu-Xia Deng, Noriko Funato, Keiji Moriyama.   

Abstract

BACKGROUND: Apert syndrome (AS) is characterized by craniosynostosis, midfacial hypoplasia, and bony syndactyly. It is an autosomal dominantly inherited disease caused by point mutations (S252W or P253R) in fibroblast growth factor receptor (FGFR) 2. These mutations cause activation of FGFR2 depending on ligand binding. Recently, an AS mouse model, Fgfr2(+/) (S252W) , showed phenotypes similar to those of AS patients. We previously reported that the soluble form of FGFR2(S252W) (sFGFR2IIIc(S252W) ) efficiently inhibits enhanced osteoblastic differentiation caused by FGFR2 activation in AS in vitro, presumably because FGFs binding to FGFRs is interrupted. In this study, we developed Fgfr2(+/) (S252W) (Ap) mice expressing the sFGFR2IIIc(S252W) protein, and we investigated the effects of sFGFR2IIIc(S252W) on AS-like phenotypes.
RESULTS: In Ap mice, the coronal suture (CS) was fused prematurely at P1. In addition, the mice exhibited a widened interfrontal suture (IFS) with ectopic bone and thickened cartilage formation. In Fgfr2(+/) (S252W) sFGFR2IIIc(S252W) (Ap/Sol) mice, the CS was similar to that of wild-type mice. Ap/Sol mice did not show any ectopic bone or cartilage formation in the IFS, but showed a wider IFS than that of the wild-type mice.
CONCLUSIONS: sFGFR2IIIc(S252W) may partially prevent craniosynostosis in the Apert mouse model by affecting the CS and IFS in vivo.
Copyright © 2013 The Authors Developmental Dynamics published by Wiley Periodicals, Inc. on behalf of American Association of Anatomists.

Entities:  

Keywords:  Apert syndrome; craniofacial; osteogenesis; pharmacodynamics

Mesh:

Substances:

Year:  2013        PMID: 24259495     DOI: 10.1002/dvdy.24099

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  16 in total

1.  Effects of thyroxine exposure on the Twist 1 +/- phenotype: A test of gene-environment interaction modeling for craniosynostosis.

Authors:  Emily L Durham; R Nicole Howie; Laurel Black; Grace Bennfors; Trish E Parsons; Mohammed Elsalanty; Jack C Yu; Seth M Weinberg; James J Cray
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2016-07-20

Review 2.  Research advances in Apert syndrome.

Authors:  Satrupa Das; Anjana Munshi
Journal:  J Oral Biol Craniofac Res       Date:  2017-05-25

3.  Small Peptide Modulation of Fibroblast Growth Factor Receptor 3-Dependent Postnatal Lymphangiogenesis.

Authors:  David P Perrault; Gene K Lee; Sun Young Park; Sunju Lee; Dongwon Choi; Eunson Jung; Young Jin Seong; Eun Kyung Park; Cynthia Sung; Roy Yu; Antoun Bouz; Austin Pourmoussa; Soo Jung Kim; Young-Kwon Hong; Alex K Wong
Journal:  Lymphat Res Biol       Date:  2019-01-16       Impact factor: 2.589

Review 4.  Modeling craniofacial and skeletal congenital birth defects to advance therapies.

Authors:  Cynthia L Neben; Ryan R Roberts; Katrina M Dipple; Amy E Merrill; Ophir D Klein
Journal:  Hum Mol Genet       Date:  2016-06-26       Impact factor: 6.150

Review 5.  Fibroblast growth factor signaling in skeletal development and disease.

Authors:  David M Ornitz; Pierre J Marie
Journal:  Genes Dev       Date:  2015-07-15       Impact factor: 11.361

Review 6.  The Fibroblast Growth Factor signaling pathway.

Authors:  David M Ornitz; Nobuyuki Itoh
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-03-13       Impact factor: 5.814

Review 7.  Fibroblast Growth Factor Receptor 2 (FGFR2) Mutation Related Syndromic Craniosynostosis.

Authors:  Saïd C Azoury; Sashank Reddy; Vivek Shukla; Chu-Xia Deng
Journal:  Int J Biol Sci       Date:  2017-11-02       Impact factor: 6.580

Review 8.  FGF/FGFR signaling in health and disease.

Authors:  Yangli Xie; Nan Su; Jing Yang; Qiaoyan Tan; Shuo Huang; Min Jin; Zhenhong Ni; Bin Zhang; Dali Zhang; Fengtao Luo; Hangang Chen; Xianding Sun; Jian Q Feng; Huabing Qi; Lin Chen
Journal:  Signal Transduct Target Ther       Date:  2020-09-02

Review 9.  Insights and future directions of potential genetic therapy for Apert syndrome: A systematic review.

Authors:  Nisreen Mohammed Al-Namnam; Soher Nagi Jayash; Firdaus Hariri; Zainal Ariff Abdul Rahman; Mohammed Abdullah Alshawsh
Journal:  Gene Ther       Date:  2021-02-22       Impact factor: 5.250

10.  Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis.

Authors:  Masako Yokota; Yukiho Kobayashi; Jumpei Morita; Hiroyuki Suzuki; Yoshihide Hashimoto; Yoshihiro Sasaki; Kazunari Akiyoshi; Keiji Moriyama
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.